基于《2024年意大利共识:慢性阻塞性肺疾病的三联吸入治疗》对中国慢性阻塞性肺疾病患者管理的启示OA

In China,chronic obstructive pulmonary disease(COPD)is a prevalent chronic disorder.With high incidence and mortality,it burdens both individual health and socioeconomic systems.Pharmacological treatment is essential for COPD management,and personalized therapy is key.Triple therapy combining inhaled corticosteroids(ICS),long-acting muscarinic antagonist(LAMA),and long-acting beta-agonist(LABA)has become a focal point.In 2024 Italy has refined the management of COPD patients through the establishment of an expert panel focusing on the applicability of triple therapy in order to standardize the management of patients with COPD and published the"An Italian Delphi Consensus on the Triple Inhalation Therapy in Chronic Obstructive Pulmonary Disease".This article interprets the consensus'core points on triple therapy,analyzes its applications in diverse clinical scenarios,and provides evidence-based guidance for optimizing drug selection in Chinese COPD treatment.The goal is to improve treatment standardization and enhance patient outcomes.